Table 2 Association of ADNI-mem, tau (flortaucipir) and Aβ (florbetapir) uptake for CSF sTREM2 baseline concentrations and rates of change over time (slope).

Variable	Entire cohort (n = 1001)		A− /TN− (n = 246)		A+ /TN− (n = 166)		A− /TN+ (n = 182)		A+ /TN+ (n = 407)
Variable	β	P-value	β	P-value	β	P-value	β	P-value	β	P-value
ADNI-mem
CSF sTREM2	− 0.028	0.346	0.032	0.606	− 0.029	0.714	− 0.039	0.588	0.009	0.863
CSF sTREM2 slope	− 0.105	0.042	− 0.057	0.575	− 0.12	0.323	− 0.013	0.904	− 0.004	0.96
Aβ-PET
CSF sTREM2	0.026	0.448	0.141	0.059	0.09	0.339	− 0.016	0.849	− 0.045	0.486
CSF sTREM2 slope	0.178	< 0.001	0.316	0.013	0.157	0.192	0.214	0.098	− 0.015	0.887
Tau-PET
CSF sTREM2	− 0.067	0.382	− 0.135	0.369	0.039	0.818	0.176	0.313	− 0.425	0.027
CSF sTREM2 slope	− 0.013	0.899	− 0.01	0.96	− 0.096	0.665	− 0.393	0.062	− 0.224	0.507
Aβ-PET rate of change
CSF sTREM2	− 0.2	0.684	0.1	0.269	0.126	0.321	0.056	0.605	− 0.214	0.014
CSF sTREM2 slope	0.063	0.304	− 0.057	0.665	− 0.309	0.038	0.246	0.078	0.079	0.465
Tau-PET rate of change
CSF sTREM2	− 0.218	0.011	− 0.355	0.021	− 0.074	0.7	− 0.116	0.55	− 0.476	0.028
CSF sTREM2 slope	− 0.031	0.795	− 0.162	0.42	− 0.369	0.008	0.218	0.393	− 0.099	0.789

Analyses adjusted for age, sex and APOE e4/PET scan. Baseline cognition was included in the model when predicting ADNI-mem at follow-up.
Significant values are given in bold.
Aβ amyloid β, A+ /− amyloid-β positive/negative, ADNI Alzheimer’s disease neuroimaging initiative, ATN Aβ deposition, tau pathology and neurodegeneration, β beta, sTREM2 soluble triggering receptor expressed on myeloid cell 2, β standardized beta, TN+ /− tau/neurodegeneration positive/negative.

Quick links

Search